Cargando…

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive and incurable lymphoma. Standard of care for younger patients with MCL is induction chemotherapy followed by autologous stem cell transplantation (auto-HCT). Rituximab maintenance after auto-HCT has been shown to improve progression-free surviv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Robert W., Palmer, Joycelynne M., Tomassetti, Sarah, Popplewell, Leslie L., Alluin, Jessica, Chomchan, Pritsana, Nademanee, Auayporn P., Siddiqi, Tanya, Tsai, Ni-Chun, Chen, Lu, Zuo, Fay, Abary, Rosemarie, Cai, Ji-lian, Herrera, Alex F., Rossi, John J., Rosen, Steven T., Forman, Stephen J., Kwak, Larry W., Holmberg, Leona A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022297/ https://www.ncbi.nlm.nih.gov/pubmed/29954415 http://dx.doi.org/10.1186/s13045-018-0631-3

Ejemplares similares

Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells
por: Zhou, Jiehua, et al.
Publicado: (2013)

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
por: Gressin, Rémy, et al.
Publicado: (2019)

Interplay between HIV-1 infection and host microRNAs
por: Sun, Guihua, et al.
Publicado: (2012)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
por: van Keep, Marjolijn, et al.
Publicado: (2016)

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
por: Zhao, Ling-Ling, et al.
Publicado: (2015)

The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma
por: Uziel, Orit, et al.
Publicado: (2014)

A phase II study of sirolimus, tacrolimus, and rabbit anti-thymocyte globulin as graft-versus-host prophylaxis after unrelated-donor peripheral blood stem cell transplant
por: Khaled, Samer K., et al.
Publicado: (2012)

Bortezomib/ibrutinib/rituximab: Various toxicities: case report
Publicado: (2021)

Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab
por: Hui, Jessica W., et al.
Publicado: (2020)

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
por: Leshchenko, Violetta V., et al.
Publicado: (2015)

CRED9: a differentially expressed elncRNA regulates expression of transcription factor CEBPA
por: Setten, Ryan L., et al.
Publicado: (2021)

Conditional Survival and Cause-specific Mortality after Autologous Hematopoietic Cell Transplantation for Hematological Malignancies
por: VanderWalde, Ari M., et al.
Publicado: (2012)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy
por: Maleki, Arash, et al.
Publicado: (2022)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
por: Kim, Areumnuri, et al.
Publicado: (2015)

Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation
por: Malki, Monzr M. Al, et al.
Publicado: (2019)

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
por: Yang, David T, et al.
Publicado: (2008)

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
por: Zhang, Shijia, et al.
Publicado: (2020)

3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma
por: Feng, Min, et al.
Publicado: (2021)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab
por: Kuang, Chaoyuan, et al.
Publicado: (2020)

Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia
por: Yao, Mingkang, et al.
Publicado: (2022)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

Leuconostoc sp. Meningitis in a Patient Treated with Rituximab for Mantle Cell Lymphoma
por: Holik, Hrvoje, et al.
Publicado: (2015)

High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency
por: Takahashi, Mayumi, et al.
Publicado: (2016)

Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy
por: Takahashi, Mayumi, et al.
Publicado: (2019)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth
por: Qu, Fu-Lian, et al.
Publicado: (2015)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
por: Li, Shi-Jun, et al.
Publicado: (2020)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates
por: Ide, Kentaro, et al.
Publicado: (2015)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report
por: Adashek, Michael, et al.
Publicado: (2018)

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab
por: Marcacci, Gianpaolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ng3q0v7kcct0sfh1e44v6gi8p8